Ann: ZolpiMist Market Update, page-58

Remember at the moment SUD dont have any approval for any of its products - Teva have not yet been given approval for Zolpimist (submitted last December so we should get some news before end of the year - EddingPharma are yet to submit an application - SUD have not submitted a application (they keep talking about it but now close two years late with their planned date).

So far no other Zolpimist deals - a lot of spin about other deals being close but nothing actually reported.

Cash they only had around $2.5m cash left at the end of the last quarter - they only expect to spend around $570k in the current quarter - we should get around $400K from the SUD 001 deal and February should see a tax return - so if they can keep to planned spend and get the income from SUD 001 deal and maybe a milestone payment from Teva we could end year with around $2.2m

So we a focus on spending we may not need a cr for at least 9 to 12 months

But lets see what the actual spend is when we get the next 4C